GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW 119,800
-7,100 (-5.59%)
Last updated: Jun 8, 2026, 2:03 PM KST
GC Biopharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -13,896 | -4,674 | -26,280 | -26,632 | 65,453 | 123,212 |
Depreciation & Amortization | 88,154 | 87,655 | 81,034 | 75,899 | 65,096 | 55,904 |
Loss (Gain) From Sale of Assets | -75,426 | -40,867 | 2,511 | 2,919 | -40,657 | -6,991 |
Asset Writedown & Restructuring Costs | 94,861 | 94,770 | 18,088 | - | - | - |
Loss (Gain) From Sale of Investments | -5,016 | 9,380 | -6,665 | -1,209 | 660 | 333 |
Loss (Gain) on Equity Investments | 18,612 | -14,582 | 27,464 | 38,431 | 18,099 | -81,533 |
Provision & Write-off of Bad Debts | 3,151 | 4,354 | 1,079 | 2,789 | 2,246 | 6,980 |
Other Operating Activities | 18,657 | -11,261 | -6,594 | 2,649 | 17,119 | 47,052 |
Change in Accounts Receivable | -9,248 | -27,413 | 52,815 | -47,093 | 13,219 | -10,756 |
Change in Inventory | -34,637 | -124,673 | -229,626 | -69,234 | 1,721 | -14,919 |
Change in Accounts Payable | -19,571 | 19,101 | 12,077 | 22,689 | 4,011 | -16,463 |
Change in Other Net Operating Assets | 95,502 | 107,673 | 20,637 | -6,681 | -27,813 | 23,160 |
Operating Cash Flow | 161,144 | 99,463 | -53,460 | -5,473 | 119,154 | 125,979 |
Operating Cash Flow Growth | - | - | - | - | -5.42% | 250.20% |
Capital Expenditures | -95,382 | -72,362 | -31,992 | -79,087 | -57,996 | -102,321 |
Sale of Property, Plant & Equipment | 2,114 | 2,109 | 791.34 | 1,319 | 1,540 | 565.21 |
Cash Acquisitions | -9,151 | -62,261 | - | - | -74,053 | 11,918 |
Divestitures | 47,035 | - | 215.13 | - | - | - |
Sale (Purchase) of Intangibles | -32,705 | -31,790 | -9,602 | -45,914 | -36,694 | -21,143 |
Investment in Securities | -50,926 | -26,828 | -24,226 | -25,139 | -31,332 | -30,734 |
Other Investing Activities | 973.4 | 957.11 | 2,269 | -1,423 | -723.7 | 10,133 |
Investing Cash Flow | -133,630 | -186,790 | -67,894 | -150,243 | -205,259 | -132,077 |
Short-Term Debt Issued | - | 1,053,063 | 1,221,140 | 1,188,247 | 806,151 | 869,500 |
Long-Term Debt Issued | - | 168,555 | 279,387 | 5,000 | 30,608 | 209,429 |
Total Debt Issued | 1,450,084 | 1,221,618 | 1,500,527 | 1,193,247 | 836,759 | 1,078,929 |
Short-Term Debt Repaid | - | -1,067,201 | -1,169,646 | -1,059,800 | -721,740 | -992,600 |
Long-Term Debt Repaid | - | -24,142 | -217,342 | -9,419 | -135,590 | -102,423 |
Total Debt Repaid | -1,516,649 | -1,091,343 | -1,386,988 | -1,069,219 | -857,330 | -1,095,023 |
Net Debt Issued (Repaid) | -66,565 | 130,275 | 113,538 | 124,028 | -20,571 | -16,094 |
Dividends Paid | -18,858 | -18,831 | -19,532 | -24,825 | -23,985 | -18,511 |
Other Financing Activities | 137.36 | 136.15 | -160.89 | 1,308 | 42,075 | -6,665 |
Financing Cash Flow | -85,286 | 111,580 | 93,845 | 100,512 | -2,481 | -41,270 |
Foreign Exchange Rate Adjustments | 8,903 | 2,556 | 366.22 | -455.39 | 7,891 | 1,141 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - | - |
Net Cash Flow | -48,869 | 26,809 | -27,143 | -55,660 | -80,694 | -46,228 |
Free Cash Flow | 65,762 | 27,101 | -85,452 | -84,560 | 61,158 | 23,658 |
Free Cash Flow Growth | - | - | - | - | 158.51% | - |
Free Cash Flow Margin | 3.22% | 1.36% | -5.09% | -5.20% | 3.57% | 1.54% |
Free Cash Flow Per Share | 5761.99 | 2374.52 | -7487.16 | -7408.97 | 5358.56 | 2072.84 |
Cash Interest Paid | 37,877 | 38,332 | 38,139 | 24,080 | 19,378 | 13,546 |
Cash Income Tax Paid | 8,992 | 11,141 | 2,468 | 19,033 | 37,349 | 18,867 |
Levered Free Cash Flow | 94,644 | -2,151 | -119,077 | -166,642 | 52,929 | -10,238 |
Unlevered Free Cash Flow | 127,143 | 29,284 | -93,803 | -148,840 | 64,424 | -2,425 |
Change in Working Capital | 32,046 | -25,312 | -144,097 | -100,319 | -8,862 | -18,978 |